CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 36 enrolled
Drug / intervention
bimatoprost solution 0.03% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01391286
NCT01391286Phase 3Completed

A Multicenter, Double-masked, Randomized, Parallel-group Study Assessing the Safety and Efficacy of Once-daily Application of Bimatoprost Solution 0.03% Compared to Vehicle to Treat Chemotherapy-induced Hypotrichosis of the Eyelashes in Japanese Subjects

Allergan·interventional·Posted Jul 12, 2011·Updated Jul 8, 2019

In Brief

A Phase 3 clinical trial evaluating bimatoprost solution 0.03% and bimatoprost vehicle solution for Eyelash Hypotrichosis. Completed, enrolled 36 participants across 1 site.

Detailed Summary

This study will evaluate the safety and efficacy of bimatoprost solution 0.03% compared with vehicle in Japanese adults with hypotrichosis of the eyelashes following chemotherapy treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 12, 2011
Enrollment StartJul 1, 2011
Primary CompletionMay 25, 2012
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.0 years ago

Interventions

bimatoprost solution 0.03%drug

One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.

bimatoprost vehicle solutiondrug

One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.